Search PubMed⌕ Search

Biomedical subjects

B Clotet

Publications and source records attributed to B Clotet.

At least 199 records · Page 11Linked to original sources
PubMed1984

Incidence and clinical significance of anti-ENA antibodies in systemic lupus erythematosus. Estimation by counterimmunoelectrophoresis.

Eighty-two patients with systemic lupus erythematosus (SLE) were investigated for the presence and significance of serum antibodies to Extractable Nuclear Antigen (ENA) and its major components, RNP, Sm and SS-B (or Ha). The counterimmunoelectrophoresis assay allowed independent detection and measurement of antibodies to the different components. Forty patients had anti-ENA antibodies, 25 (30%) were of anti-RNP type alone or anti-RNP associated with anti-Sm, and 12 (15%) were of anti-RNP type alone. Anti-ENA antibodies distinguished a subset of patients with less common incidence of renal disease, positive Coombs test, anticoagulant serum factors and high titres of anti-DNAds antibodies, with higher incidence of Raynaud's phenomenon, swollen hands, hypergammaglobulinemia and high titres of antinuclear antibodies with speckled pattern on immunofluorescence. SLE patients with anti-RNP antibodies had in addition a high frequency of normal complement values. All but one SLE patient with only anti-RNP antibodies fulfilled at least four or more criteria for the diagnosis of SLE. We conclude that anti-ENA antibodies in SLE patients are associated with a low prevalence of nephritis and a clinical and laboratory profile similar to that of the MCTD syndrome. These findings demonstrate the difficulty of inferring rigid differences between MCTD and SLE. The MCTD syndrome probably represents only one segment of the whole clinical spectrum of SLE.

Antibodies, Antinuclear↗
PubMed1980

[Treatment of acute brucellosis with cotrimoxazole, doxicyclin and streptomycin. A comparative study (author's transl)].

Human brucellosis can be managed with different therapeutic measures. The present study compares the therapeutic efficacy of the classical treatment with streptomycin, doxicyclin and cotrimoxazole, every one of the treatment regimes being applied to 19 patients with acute brucellosis. The results do not demonstrate an advantage of the new association over the classical treatment. Relapses, time elapsed until the patient was afebrile and drug tolerance were similar for both treatments. The classical treatment has a lower cost but the new association implies more patient comfort because the number of pills to be ingested daily is reduced to less than half, a fact that could make it the treatment of choice.

Acute Disease↗
PubMed1980

Antithrombin III contribution to cholestasis differential diagnosis: its correlation with one stage prothrombin time and factor V.

Levels of antithrombin III (AT III) measured by two different methods, Factor V (FV) and One Stage Prothrombin Time, have been studied in two groups of patients: 55 with chronic liver disease and 22 with extra hepatic cholestasis. Results show a statistically significant correlation between the decrease of AT III and FV in the first group, and the normality of these parameters (unrelated to One Stage Prothrombin Time) in the second group. Levels at AT III and FV correlate directly with the functional integrity of hepatic parenchyma, so they may help in the differential diagnosis of different types of cholestasis.

Antithrombin III↗